Christian Nicolaj Andreassen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christian Nicolaj Andreassen has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Jan Alsner
Aarhus University Hospital
20 shared publications Jens Overgaard
A Department of Experimental Clinical Oncology , Aarhus University Hospital , Aarhus , Denmark
10 shared publications- Alison Margaret Dunning
University of Cambridge, Cambridge, United Kingdom
7 shared publications - Catharine Mary Louise West
The University of Manchester, Manchester, United Kingdom
7 shared publications - Søren Møller Bentzen
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland; Epidemiology and Public Health, University of Maryland, Baltimore, Maryland
7 shared publications Barry S. Rosenstein
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
6 shared publications
Latest Publications
- Open Access
- 27 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 60
A genome-wide association study on radiation induced fibrosis in breast cancer patients
- 27 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 60
Open AccessA genome-wide association study on radiation induced fibrosis in breast cancer patients
- Open Access
- 19 March 2026
- Published by Elsevier in SSRN Electronic Journal
A Genome-Wide Association Study on Radiation Induced Fibrosis in Breast Cancer Patients
Background and purposeRadiation-induced fibrosis affects women having undergone post-lumpectomy radiotherapy to a varying degree. Publications have identified Single Nucleotide Polymorphisms (SNPs) associated with fibrosis after radiotherapy in breast cancer patients. We aimed to identify new genetic variants in a cohort of early breast cancer patients representing two cohorts treated within the Danish Breast Cancer Group (DBCG) protocols.Patients/material and methodsThe genome-wide-association-analysis included 869 patients treated with lumpectomy and adjuvant radiotherapy in the DBCG trials hypo- versus normofractionated radiotherapy trial, DBCG-HYPO, and the DBCG partial versus whole breast irradiation trial, DBCG-PBI.Samples were genotyped using the Illumina Infinium OncoArray Bead Chip. Associations between common genetic variants and fibrosis grade 2 or 3 (LENT-SOMA) in a per-risk allele log-additive genetic model were tested in an exploratory genome-wide association study (GWAS). A genome-wide significance cut-off of P < 5x10-8 was applied.ResultsAn association reaching a P-value = 5.90 x10-8 after removal of principal component outliers was identified in a locus on chromosome 10. The strongest association was represented by the SNP rs75542274.InterpretationAn exploratory GWAS identified a locus on chromosome 10 reaching a near-significant genome-wide association with radiation-induced fibrosis. This finding must be tested in – or meta-analysed with - independent studies.
- 19 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Genome-Wide Association Study on Radiation Induced Fibrosis in Breast Cancer Patients
Background and purposeRadiation-induced fibrosis affects women having undergone post-lumpectomy radiotherapy to a varying degree. Publications have identified Single Nucleotide Polymorphisms (SNPs) associated with fibrosis after radiotherapy in breast cancer patients. We aimed to identify new genetic variants in a cohort of early breast cancer patients representing two cohorts treated within the Danish Breast Cancer Group (DBCG) protocols.Patients/material and methodsThe genome-wide-association-analysis included 869 patients treated with lumpectomy and adjuvant radiotherapy in the DBCG trials hypo- versus normofractionated radiotherapy trial, DBCG-HYPO, and the DBCG partial versus whole breast irradiation trial, DBCG-PBI.Samples were genotyped using the Illumina Infinium OncoArray Bead Chip. Associations between common genetic variants and fibrosis grade 2 or 3 (LENT-SOMA) in a per-risk allele log-additive genetic model were tested in an exploratory genome-wide association study (GWAS). A genome-wide significance cut-off of P < 5x10-8 was applied.ResultsAn association reaching a P-value = 5.90 x10-8 after removal of principal component outliers was identified in a locus on chromosome 10. The strongest association was represented by the SNP rs75542274.InterpretationAn exploratory GWAS identified a locus on chromosome 10 reaching a near-significant genome-wide association with radiation-induced fibrosis. This finding must be tested in – or meta-analysed with - independent studies.
- 1 April 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 103 (5) , 1203-1211
Comparison of Coding Transcriptomes in Fibroblasts Irradiated With Low and High LET Proton Beams and Cobalt-60 Photons
- 1 April 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 103 (5) , 1203-1211
Comparison of Coding Transcriptomes in Fibroblasts Irradiated With Low and High LET Proton Beams and Cobalt-60 Photons
- 1 November 2018
- Published by Elsevier in Oral Oncology
- Vol. 86, 91-99
IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer
- 1 November 2018
- Published by Elsevier in Oral Oncology
- Vol. 86, 91-99
IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer
- 8 September 2017
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 56 (11) , 1406-1412
Differential gene expression in primary fibroblasts induced by proton and cobalt-60 beam irradiation
Proton beam therapy delivers a more conformal dose distribution than conventional radiotherapy, thus improving normal tissue sparring. Increasing linear energy transfer (LET) along the proton track increases the relative biological effectiveness (RBE) near the distal edge of the Spread-out Bragg peak (SOBP). The severity of normal tissue side effects following photon beam radiotherapy vary considerably between patients. The dual study aim was to identify gene expression patterns specific to radiation type and proton beam position, and to assess whether individual radiation sensitivity influences gene expression levels in fibroblast cultures irradiated in vitro. The study includes 30 primary fibroblast cell cultures from patients previously classified as either radiosensitive or radioresistant. Cells were irradiated at three different positions in the proton beam profile: entrance, mid-SOBP and at the SOBP distal edge. Dose was delivered in three fractions × 3.5 Gy(RBE) (RBE 1.1). Cobalt-60 (Co-60) irradiation was used as reference. Real-time qPCR was performed to determine gene expression levels for 17 genes associated with inflammation response, fibrosis and angiogenesis. Differences in median gene expression levels were observed for multiple genes such as IL6, IL8 and CXCL12. Median IL6 expression was 30%, 24% and 47% lower in entrance, mid-SOBP and SOBP distal edge groups than in Co-60 irradiated cells. No genes were found to be oppositely regulated by different radiation qualities. Radiosensitive patient samples had the strongest regulation of gene expression; irrespective of radiation type. Our findings indicate that the increased LET at the SOBP distal edge position did not generally lead to increased transcriptive response in primary fibroblast cultures. Inflammatory factors were generally less extensively upregulated by proton irradiation compared with Co-60 photon irradiation. These effects may possibly influence the development of normal tissue damage in patients treated with proton beam therapy.
- 8 September 2017
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 56 (11) , 1406-1412
Differential gene expression in primary fibroblasts induced by proton and cobalt-60 beam irradiation
Proton beam therapy delivers a more conformal dose distribution than conventional radiotherapy, thus improving normal tissue sparring. Increasing linear energy transfer (LET) along the proton track increases the relative biological effectiveness (RBE) near the distal edge of the Spread-out Bragg peak (SOBP). The severity of normal tissue side effects following photon beam radiotherapy vary considerably between patients. The dual study aim was to identify gene expression patterns specific to radiation type and proton beam position, and to assess whether individual radiation sensitivity influences gene expression levels in fibroblast cultures irradiated in vitro. The study includes 30 primary fibroblast cell cultures from patients previously classified as either radiosensitive or radioresistant. Cells were irradiated at three different positions in the proton beam profile: entrance, mid-SOBP and at the SOBP distal edge. Dose was delivered in three fractions × 3.5 Gy(RBE) (RBE 1.1). Cobalt-60 (Co-60) irradiation was used as reference. Real-time qPCR was performed to determine gene expression levels for 17 genes associated with inflammation response, fibrosis and angiogenesis. Differences in median gene expression levels were observed for multiple genes such as IL6, IL8 and CXCL12. Median IL6 expression was 30%, 24% and 47% lower in entrance, mid-SOBP and SOBP distal edge groups than in Co-60 irradiated cells. No genes were found to be oppositely regulated by different radiation qualities. Radiosensitive patient samples had the strongest regulation of gene expression; irrespective of radiation type. Our findings indicate that the increased LET at the SOBP distal edge position did not generally lead to increased transcriptive response in primary fibroblast cultures. Inflammatory factors were generally less extensively upregulated by proton irradiation compared with Co-60 photon irradiation. These effects may possibly influence the development of normal tissue damage in patients treated with proton beam therapy.
- 26 August 2017
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 56 (11) , 1514-1521
Validation of genetic predictors of late radiation-induced morbidity in prostate cancer patients
Introduction: Normal tissue morbidity sets the dose limit for radiotherapy (RT) in cancer treatment and has importance for quality of life for cancer survivors. A previous study of prostate cancer patients treated with RT generated clinical data for radiation-induced morbidity measured by anorectal physiological methods and validated questionnaires. Other studies have identified genetic predictors associated with late radiation-induced morbidity outcome. We have expanded biobank material aiming to validate single nucleotide polymorphisms (SNPs) and a gene expression classifier with endpoints on patient-reported outcomes and biomechanical properties of the anorectum from our cohort matching originally published endpoints. Materials and methods: The present cohort of prostate cancer patients was treated with RT curative intent in 1999–2007. Nine SNPs associated with late radiation-induced morbidity were tested in 96 patients (rs2788612, rs1800629, rs264663, rs2682585, rs2268363, rs1801516, rs13035033, rs7120482 and rs17779457). A validated gene expression profile predictive of resistance to radiation-induced skin fibrosis was tested in 42 patients. An RT-induced anorectal dysfunction score (RT-ARD) served as a fibrosis-surrogate and a measure of overall radiation-induced morbidity. Results: The lowest p-value found in the genotype analyses was for SNP rs2682585 minor allele (A) in the FSHR gene and the RT-ARD score with odds ratios (OR) = 1.76; 95% CI (0.98–3.17) p = .06, which was out of concordance with original data showing a protective effect of the minor allele. The gene expression profile in patients classified as fibrosis-resistant was associated with high RT-ARD scores OR 4.18; 95% CI (1.1–16.6), p = .04 conflicting with the hypothesis that fibrosis-resistant patients would experience lower RT-ARD scores. Conclusions: We aimed to validate nine SNPs and a gene expression classifier in a cohort of prostate cancer patients with unique scoring of radiation-induced morbidity. One significant association was found, pointing to the opposite direction of originally published data. We conclude that the material was not able to validate previously published genetic predictors of radiation-induced morbidity.
- 26 August 2017
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 56 (11) , 1514-1521
Validation of genetic predictors of late radiation-induced morbidity in prostate cancer patients
Introduction: Normal tissue morbidity sets the dose limit for radiotherapy (RT) in cancer treatment and has importance for quality of life for cancer survivors. A previous study of prostate cancer patients treated with RT generated clinical data for radiation-induced morbidity measured by anorectal physiological methods and validated questionnaires. Other studies have identified genetic predictors associated with late radiation-induced morbidity outcome. We have expanded biobank material aiming to validate single nucleotide polymorphisms (SNPs) and a gene expression classifier with endpoints on patient-reported outcomes and biomechanical properties of the anorectum from our cohort matching originally published endpoints. Materials and methods: The present cohort of prostate cancer patients was treated with RT curative intent in 1999–2007. Nine SNPs associated with late radiation-induced morbidity were tested in 96 patients (rs2788612, rs1800629, rs264663, rs2682585, rs2268363, rs1801516, rs13035033, rs7120482 and rs17779457). A validated gene expression profile predictive of resistance to radiation-induced skin fibrosis was tested in 42 patients. An RT-induced anorectal dysfunction score (RT-ARD) served as a fibrosis-surrogate and a measure of overall radiation-induced morbidity. Results: The lowest p-value found in the genotype analyses was for SNP rs2682585 minor allele (A) in the FSHR gene and the RT-ARD score with odds ratios (OR) = 1.76; 95% CI (0.98–3.17) p = .06, which was out of concordance with original data showing a protective effect of the minor allele. The gene expression profile in patients classified as fibrosis-resistant was associated with high RT-ARD scores OR 4.18; 95% CI (1.1–16.6), p = .04 conflicting with the hypothesis that fibrosis-resistant patients would experience lower RT-ARD scores. Conclusions: We aimed to validate nine SNPs and a gene expression classifier in a cohort of prostate cancer patients with unique scoring of radiation-induced morbidity. One significant association was found, pointing to the opposite direction of originally published data. We conclude that the material was not able to validate previously published genetic predictors of radiation-induced morbidity.
- Open Access
- 27 April 2017
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 7, 83
Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era
The ability to stratify patients using a set of biomarkers that predicts toxicity risk would allow for radiotherapy modulation and serve as a valuable tool for precision medicine and personalized radiotherapy (RT). For patients presenting with tumors with a low risk of recurrence, modifying RT schedules to avoid toxicity would be clinically advantageous. Indeed, for the patient at low risk of developing radiation associated toxicity, use of a hypofractionated protocol could be proposed leading to treatment time reduction and a cost-utility advantage. Conversely, for patients predicted to be at high risk for toxicity, either a more conformal form or a new technique of RT, or a multidisciplinary approach employing surgery could be included in the trial design to avoid or mitigate RT when the potential toxicity risk may be higher than the risk of disease recurrence. In addition, for patients at high risk of recurrence and low risk of toxicity, dose escalation, such as a greater boost dose or irradiation field extensions could be considered to improve local control without severe toxicities, providing enhanced clinical benefit. In cases of high risk of toxicity, tumor control should to be prioritized. In this review, toxicity biomarkers with sufficient evidence for clinical testing will be presented. In addition, clinical trial designs and predictive models will be described for different clinical situations.
- 27 April 2017
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 7, 83
Open AccessData-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era
The ability to stratify patients using a set of biomarkers that predicts toxicity risk would allow for radiotherapy modulation and serve as a valuable tool for precision medicine and personalized radiotherapy (RT). For patients presenting with tumors with a low risk of recurrence, modifying RT schedules to avoid toxicity would be clinically advantageous. Indeed, for the patient at low risk of developing radiation associated toxicity, use of a hypofractionated protocol could be proposed leading to treatment time reduction and a cost-utility advantage. Conversely, for patients predicted to be at high risk for toxicity, either a more conformal form or a new technique of RT, or a multidisciplinary approach employing surgery could be included in the trial design to avoid or mitigate RT when the potential toxicity risk may be higher than the risk of disease recurrence. In addition, for patients at high risk of recurrence and low risk of toxicity, dose escalation, such as a greater boost dose or irradiation field extensions could be considered to improve local control without severe toxicities, providing enhanced clinical benefit. In cases of high risk of toxicity, tumor control should to be prioritized. In this review, toxicity biomarkers with sufficient evidence for clinical testing will be presented. In addition, clinical trial designs and predictive models will be described for different clinical situations.
- 1 December 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 121 (3) , 431-439
Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients
- 1 December 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 121 (3) , 431-439
Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients
- 1 November 2016
- Published by Elsevier in Cancer Letters
- Vol. 382 (1) , 127-136
Radiogenomics – current status, challenges and future directions
- 1 November 2016
- Published by Elsevier in Cancer Letters
- Vol. 382 (1) , 127-136
Radiogenomics – current status, challenges and future directions
- 1 September 2016
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 55 (12) , 1498-1500
Radiation-induced morbidity evaluated by high-frequency ultrasound
(2016). Radiation-induced morbidity evaluated by high-frequency ultrasound. Acta Oncologica: Vol. 55, No. 12, pp. 1498-1500.
- 1 September 2016
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 55 (12) , 1498-1500
Radiation-induced morbidity evaluated by high-frequency ultrasound
(2016). Radiation-induced morbidity evaluated by high-frequency ultrasound. Acta Oncologica: Vol. 55, No. 12, pp. 1498-1500.